NR4A1 and breast cancer: We have started the trial ICON (CA209-9FN), a randomized phase IIb study evaluating Immunogenic chemotherapy COmbined with ipilimumab and Nivolumab in patients with hormone receptor positive metastatic BC (HR + mBC).